INTRODUCTION
Hematopoietic stem cell transplantation (HCT) from HLA-mismatched family donors is a potentially curative option for patients with high-risk hematologic malignancies lacking an HLAmatched donor 1, 2 . For haploidentical HCT, this procedure typically requires rigorous T cell depletion of the graft eliminating the cellular component that can contribute to the curative potential of an allogeneic HCT 3 . To overcome this limitation donor-derived lymphocytes have been infused later post-transplant to provide a graft-versus-malignancy effect. Although preclinical and clinical studies were initiated to minimize the side effects of such a procedure 4, 5 , the risk of inducing severe graft-versus-host-disease (GVHD) remains substantial and relapse rates continue to be significant in part due to tumor escape mechanisms that evolve over time 6 .
Enforced expression of T cell receptor (TCR) genes directed against a tumor-associated antigen (TAA) has been explored as a means by which the potency of T cell adoptive transfer (AT) may be augmented. When using allogeneic T cells, such an approach may serve to direct the donor T cell response preferentially to the host leukemia cells instead of the normal host cells, thereby increasing the therapeutic index of T cell AT. Lessons from studies of murine autologous T cell AT models have shown that: 1. TCR gene therapy can be expected to break tolerance against self-antigens such as tumor-associated antigens; 2. with few exceptions TCR gene transfer was associated with an acceptable toxicity profile; and 3. the transfer of TCR-engineered T cells has been shown to impact large tumor burdens 7 .
However, clinical translation of TCR gene-modified T cell AT has been hampered by the growing evidence that in vivo proliferation and persistence of engineered T cells is more limited than needed for an optimal anti-tumor response 8, 9 . Increasingly, T cell AT is performed in the Here, we evaluated the converse concept that the in vivo infusion of T cells forced to express a tumor-specific antigen could be driven to expand and persist as a result of host alloantigen signaling of the endogenous TCR, thereby providing a potent GVL effect. In a fully mismatched murine HCT model T cells were transduced with a TCR directed against a surrogate leukemiaassociated antigen, characterized in vitro and evaluated in the transplant setting. Our studies demonstrate that TCR transfer into allogeneic T cells can result in a functionally relevant downregulation of the endogenous TCR that accounts for its capacity for alloresponse. Whereas GVL effects mediated by TCR-engineered CD8 + T cells were achieved after AT early post-HCT, anti-leukemic effects were completely abolished if given later post-HCT. We further show that GVL effects after early AT are associated with prominent in vivo skewing of the Vβ-families within the transferred T cell population. After late AT, markedly reduced oligoclonal expansion was observed and baseline PD-1 expression was higher in allogeneic than syngeneic transplant
For personal use only. on April 4, 2017. by guest www.bloodjournal.org From recipients. Notably, GVL in allogeneic recipients could be restored without GVHD induction when AT was given combined with PD-L1 blockade.
MATERIALS AND METHODS

Animals and HCT
Animals in the experiments were used under protocols approved by the State Government of Niedersachsen, Germany. C57BL/6 (B6, H-2 b ) mice were purchased from Charles River, 16 . DCs were generated as previously described and pulsed with leukemia cell lysates 4 . Single cell suspensions of donor splenocytes were co-cultured with the irradiated producer cells for 2 days in the presence of ConA (2.5 µg/ml) (Sigma, St. Louis, USA), IL2 (20 U/ml) (Amgen, Munich, Germany) and IL7 (4 ng/ml) (R&D Systems, Minneapolis, USA) in RPMI 1640 complete media (PAA, Pasching, Austria).
Controls were co-cultured on the same producer cells not containing the respective viral construct, further referred to as non-transduced controls. After priming on maturated recipientderived DCs for another two days, T cells were harvested and expanded using α -CD3/α-CD28
(BD Biosciences, Heidelberg, Germany) coated microspheres (Invitrogen, Karsluhe, Germany) in the presence of recombinant IL2 (20 U/ml) and IL7 (4 ng/ml).
Flow cytometry
The following antibodies were used: CD8α-(PE/PE-Cy7/APC-H7/PE-Cy5.5), CD4-(PE/APC/PECy7/Pacific Blue), Vα2-biotin, Vβ3-PE, Vβ4-biot., Vβ6-biot., Vβ8-PE, Vβ5-PE, PD-1-PE, CD25-PE, CD69-PE, CD44-PE, CD62L-PE, CD95L-APC, CD95-PE-Cy7, CD127 biot., annexin V-APC, (BD Biosciences, Heidelberg, Germany 
Assessment of GVHD
Clinical GVHD assessment was done in a double blinded fashion for eight weeks after AT. We used a clinical scoring system that was described previously 17 grading the animals based on weight loss, skin integrity, posture, fur texture, and activity 17 .
In vitro cytotoxicity and mixed leukocyte reaction (MLR)
The JAM assay was used to assess cytotoxicity against C1498 or C1498-OVA target cells in vitro as described 18 . MLR standard techniques were adjusted to the specific biological needs of pre- 
TCR spectratype analysis and assessment of proliferation
For TCR spectratype analysis total mRNA was transcribed into cDNA with Superscript III reverse transcriptase and oligo-dT12-18 primers (Invitrogen, Karlsruhe, Germany). cDNA was amplified by PCR for 30 Cycles with 21 Vβ-specific primers and one Cβ1-Cβ2 primer as described previously 19 . PCR products were FAM-labeled by nested primer extension and analyzed by capillary electrophoresis (ABI 3110) 20 . To determine skewing within the Vβ-family the areas under the peaks representing varying CDR3-size length were compared to the For personal use only. on April 4, 2017. by guest www.bloodjournal.org From corresponding peaks from naïve controls. A CDR3-size length was considered skewed if the area under the peak was greater than the mean + 3 SD of the respective control peak 21 . In vivo proliferation of hepatic and splenic T cells was measured by 5-bromo-2-deoxyuridine (BrdU)
incorporation.
Statistical analysis
Kaplan-Meier product-limit method was used to calculate survival rates. Differences between the groups were determined using Log-rank statistics. In other cases, statistical analyses were performed by Mann-Whitney test or by Student's t-test (two-tailed). P values < 0.05 were considered to be significant and were designated by *. P values < 0.01 were designated by **, p values less than 0.001 were designated by ***.
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RESULTS
Gene engineering of allogeneic T cells with anti-leukemia reactive TCR genes augments the
GVL effect in vitro and vivo
To determine the feasibility and the biological consequences of equipping a T cell of allogeneic origin with a TCR against a recipient leukemia-specific antigen, we transduced naïve MHC- produced some GVL effect in the cohort that received the highest cell dose only, although longterm survival was 0% ( Figure 1E ). Hypothesizing higher apoptosis rates of TCR-engineered T cells after AT, transferred cells were retrieved from the recipients after three days. Freshly isolated naïve CD8 + T cells from donor spleens were given as controls. Unexpectedly, apoptosis rates as defined by annexin V positivity were comparable (suppl. Figure 2 ).
TCR gene transfer of allogeneic T cells reduces the expression of the endogenous TCR and diminishes alloresponsiveness in vitro
To determine whether the retrovirally introduced TCR might impact the expression of endogenous TCRs directed against host alloantigens, we assessed alloreactivity in vitro. 
TCR-transduced CD8 + T cells mediate strong GVL effects with decreased GVHD rates when administered early after HCT.
To assess the GVHD-triggering potential of the TCR-engineered T cell product an inflammatory post-transplant milieu was chosen known to facilitate severe in vivo alloreactivity 22 .
Hypothesizing that an inflammatory environment might promote in vivo persistence and as a Figure 3D ). Upon AT only 2/21 Vβ-families were skewed indicating that oligoclones must have grown out after transfer. Of note, the Vβ-family harboring the introduced gene (Vβ 5.2) was reproducibly detectable in all samples. Whereas in the syngeneic setting 6 families showed Vβ-shifts, more prominent (13/21) shifts were found in the allogeneic setting (Table 1 ). In vivo, this is associated with a certain degree of GVHD in these mice suggesting oligoclonal expansion driven by alloreactivty.
Allogeneic TCR-transduced CD8
+ T cells fail to induce GVL when given later after HCT.
Delayed AT of allogeneic T cells has the potential for strong GVL effects and reduced GVHD due to absence of lymphopenia, repair of tissue injury, and presence of donor APCs while still permitting a graft-vs-lymphohematopoietic effect to occur, especially since fewer T cells may be required to mediate GVL than GVHD lethality 23 . To further reduce the risk of GVHD but aiming to maintain strong GVL effects we evaluated the biological consequences of late AT. We transferred either allogeneic (B10.A) or syngeneic (B6) TCR-transduced T cells into full allogeneic chimeras (B10.A → B6) or syngeneic transplant recipients (B6 → B6) and monitored the peripheral blood for GFP-expressing cells. Allogeneic T cells showed a decline from day one to day seven whereas the frequencies of syngeneic TCR-transduced T cells remained similar ( Figure 4A ). When we administered C1498-OVA 3 days after AT, GVL effects were completely abolished. In contrast, consistent rescue rates of ~60% could be documented after syngeneic AT ( Figure 4B ). The interval between AT and leukemia challenge, C1498-OVA, was shortened to 1 day. Here, 85% of mice were rescued in the allogeneic setting suggesting that TCR-transduced T cells were functional, at least 1 day after AT (suppl. Figure 3) . Clinical monitoring for GVHD did Figure 5A ). This effect was more pronounced within the CD8 + population with the high affinity allo-endogenous TCR on day three after AT.
To evaluate whether reduced numbers in the periphery might reflect a different migration pattern of allogeneic T cells lymph nodes, spleen, and bone marrow were analyzed for the respective T cell population. Allogeneic T cells were reduced in all organs analyzed on day three after AT, which again was more pronounced for 2C than polyclonal T cells ( Figure 5A ). To determine whether low frequencies of allogeneic T cells were a consequence of increased apoptosis we analyzed the transferred endogenous T cell population for annexin V, CD95, and CD95L
expression. Neither differences were observed between low and high affinity allogeneic Figure 6C ). In contrast, PD-L1 blockade restored GVL efficacy of adoptively transferred allogeneic T cells raising leukemia-free survival from 0% to 60% after AT ( Figure   6D ). Notably, mice treated with PD-L1 blockade and allogeneic TCR-transduced CD8 + T cells did not develop any signs of GVHD ( Figure 6E) . To evaluate the impact of PD-L1 blockade on the fate of transduced T cells after late AT, cells were retrieved 40 days after transfer. In contrast to the results after early AT ( 13/21, Table 1 ), spectratype analysis showed lower numbers of From these results we deduce that in the allogeneic setting an increased baseline of PD-1 expression results in a stronger impact of PD-L1-blockade after leukemia challenge.
For
DISCUSSION
The genetic transfer of TCRs is a powerful approach to rapidly generate tumor-specific T cells.
Clinical studies have focused on the use of TCR-engineered autologous T cells and outcome has been correlated with in vivo persistence of adoptively transferred T cells 8, 27, 28 . To our knowledge, our study is the first assessing the potential use of TCR-engineered T cells of allogeneic origin after MHC-mismatched hematopoietic cell transplantation. We demonstrate that donor-derived
CD8
+ T cells engineered to express a TCR against a leukemia-associated antigen mediated strong GVL effects at significantly reduced GVHD-rates when transferred early after transplant.
Delayed transfer of the same cell type was followed by rapidly decreasing cell numbers and reduced oligoclonal expansion as shown in TCR spectratype analysis. This was associated with a complete loss of GVL effects. This loss of function was accompanied with increasing PD-1 expression on adoptively transferred T cells and PD-L1 blockade widely restored GVL effects without triggering GVHD.
In vivo persistence of transferred T cells seems to be a prerequisite for significant antitumor effects. This implies that virus-specific T cells additionally equipped with a TCR directed against a tumor-associated antigen might persist longer in vivo in patients since encounter with relevant viruses would drive homoeostatic proliferation of such T cells over a longer period of time 29, 30 . Although intriguing, this concept, to our knowledge, has not been widely tested in vivo.
Modifying this concept for the setting of allogeneic HCT we hypothesized that a largely polyclonal set of alloreactive TCRs on donor-derived T cells would drive continuous in vivo proliferation propagating simultaneously transduced T cells expressing a leukemia-reactive TCR.
The transduced TCR has to compete for cell surface expression with endogenous TCRs for CD3 binding 29, 31 . Indeed, reduced expression of endogenous TCRs was observed in our 
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